Event in Progress:
Discover the latest content that has just been published on Research Tree
AbbVie delivered a mixed result in the last quarter with revenues falling below analyst expectations. However, the company did manage an earnings beat. The management has focused on the rapid development and introduction of SKYRIZI and RINVOQ for all of HUMIRA's key indications as well as a brand-new indication, atopic dermatitis. By 2027, they predict that the combined sales of these two medications will surpass the peak revenues of HUMIRA, with a strong increase anticipated until the remainder
Companies: AbbVie (ABBV:NYSE)AbbVie, Inc. (ABBV:NYS)
Baptista Research
AbbVie's results for the past quarter were mixed and the company failed to meet Wall Street expectations with respect to its revenues but managed an earnings beat. With Skyrizi and Rinvoq currently on track to produce more than $7.5 billion in combined sales this year, significantly ahead of their initial projections, immunology once again exhibited a good performance. This outcome is particularly encouraging given that Rinvoq is being used to treat atopic dermatitis and IBD and PSA are still in
AbbVie has witnessed a strong correction over the past few months and its results have also not been the best. The company’s revenues in the last result were below market expectations though it did deliver an earnings beat. The silver lining for AbbVie has been the strong growth in double-digit operational sales from immunology, where Skyrizi exceeded the expectation of the company with its impressive market share gains in both PSA and psoriasis. The recent U.S approval of Skyrizi in Crohn’s dis
Companies: AbbVie, Inc. (ABBV:NYS)AbbVie, Inc. (0QCV:LON)
AbbVie had a positive start to 2022 with total net revenue and adjusted earnings exceeding the expectations of the management. The company is seeing positive momentum over various important portfolios and products, which include strong operational revenue growth from Aesthetics, Neuroscience, Rinvoq, and Skyrizi. Skyrizi has been performing particularly well for AbbVie. In psoriasis, the company has been achieving good profits and the recent launch of Skyrizi in psoriatic arthritis and the antic
AbbVie had a decent financial result with a balanced performance demonstrated across every major growth franchise, including a double-digit equivalent operation growth in revenue from neuroscience, aesthetics, and immunology. The management is expecting to add various innovative indications to the list of approved usages for Rinvoq and Skyrizi in 2022. The company has established a prominent position with Venclexta and Imbruvica in hematological oncology. The increased promotional investments of
AbbVie has received a number of interesting FDA approvals over the past months and are on track to be either approved or under review across all of Humira's primary indications. The company's Neuroscience division has seen excellent momentum off late. In addition, they experienced solid growth in their platforms, including aesthetics and hematological oncology portfolio. Based on our credit analysis, the company merits a Credit Evaluation Score of A with a stable outlook and as per our Financial
AbbVie has received an exciting set of FDA approvals over the past few weeks which have made the company’s stock soar. In the first week of December 2021, the company announced the approval of its Vuity 1.25% prescription eye drop, the first and only FDA-approved eye drop to treat presbyopia – age-related blurry vision. AbbVie also received approval for its Rinvoq (upadacitinib; 15 mg) medication to treat patients of active psoriatic arthritis. Apart from these big approval announcements which a
AbbVie has come very close to the target price from our last report as the company delivered an outstanding quarter with adjusted earnings per share of $3.11 well ahead of the management guidance coupled with a 19.3% top-line growth on a comparable operational basis. The recovery across the company portfolio is going very well in aggregate in specific disease areas such as CLL and HCV. The management expects that these specialty areas will further recover as the year progresses. AbbVie was recen
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc
Companies: IMM IBAB 0O8G BCART 0QLR RHO5 MRCK 0QXH VSC 0QGJ SANO 0OCQ IPH GSK AZN 0Y6X QGEN 0HL9 0GRZ EJXB 0Q15 ABBV 0HAV 0RIH 0R0T BMYS EXK 0J8Z 0R29 0R34 0K3W NSTGQ 0KCC 0Q1N SGEN 0R0H 12V VNRX XE9
goetzpartners securities Limited
Research Tree provides access to ongoing research coverage, media content and regulatory news on AbbVie, Inc.. We currently have 0 research reports from 5 professional analysts.
Share: